Can chronic lorazepam exposure make abrupt cessation cause hyperexcitability and cognitive impairment?

Chronic lorazepam exposure can produce neuroadaptations that make sudden withdrawal clinically hazardous, particularly in an older adult who may be more vulnerable to confusion or delirium.

Mechanistic evidence

• Preclinical lorazepam studies show reduced cortical GABA-A α1 and γ2 subunit expression, diminished GABA responsiveness, and weaker coupling between benzodiazepine and GABA receptor sites. Chronic exposure also alters hippocampal glutamatergic transmission.
• Across benzodiazepine models, excitatory adaptations include AMPA-receptor insertion/phosphorylation, increased AMPA-to-NMDA signaling, and NMDA-dependent processes. These changes are consistent with a relative excitation–inhibition imbalance after drug removal, rather than a simple, uniform loss of GABA-A receptors.

Clinical consequences of abrupt cessation

• Abrupt discontinuation or rapid dose reduction after regular use can unmask CNS hyperexcitability: anxiety, tremor, insomnia, seizures, and delirium. Multi-society guidance warns that withdrawal may be severe or life-threatening.
• Lorazepam-specific reports include convulsive seizures after abrupt withdrawal in long-term, high-dose users, and a withdrawal-delirium case in which agitation, disorientation, fluctuating consciousness, incoherent speech, and memory problems developed within one day of stopping lorazepam and resolved within hours of restarting it.
• Acute cognitive impairment is therefore most clearly established as withdrawal-related confusion or delirium, not necessarily a persistent cognitive decline. In contrast, planned benzodiazepine withdrawal in older adults has been associated with longer-term cognitive and psychomotor improvement versus continued use.

Clinical implications

• Withdrawal severity depends on dose, duration, physical dependence, and individual neurologic vulnerability. New confusion, seizure activity, or marked autonomic/behavioral deterioration after stopping warrants urgent assessment.
• Bottom line: The claim is supported: chronic lorazepam can induce compensatory inhibitory and excitatory adaptations, and abrupt cessation can reveal hyperexcitability and acutely impair cognition, including delirium. Avoid abrupt discontinuation; an individualized gradual taper—often initially 5–10% reductions every 2–4 weeks, adjusted to symptoms—is the safer approach.